MicroRNAs as Biomarkers in First Episode Schizophrenia
NCT07703670
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study investigates whether tiny molecules called microRNAs (miRNAs), found in special brain-derived "packages" (neural-derived extracellular vesicles, or NDEs) that travel from the brain into the blood, can serve as helpful indicators (biomarkers) for schizophrenia. Currently, doctors diagnose schizophrenia and monitor treatment primarily through clinical interviews, which can be slow and imprecise.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia Disorder
- Schizophreniform Disorder
- Schizoaffective Disorder
- Psychosis Not Otherwise Specified (NOS)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 15 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Northwell Health
- Last updated on ClinicalTrials.gov
- July 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- Zucker Hillside Hospital · Glen Oaks, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.